2019 was a ground breaking year for cannabinoid derived pharmaceuticals in Europe, with growing interest in European research into their therapeutic potential. December 2019 saw the successful fast-track approval of a cannabinoid-based epilepsy drug into the UK’s NHS.
Introducing the first Cannabinoid Derived Pharmaceuticals Summit Europe. In a rapidly developing field, this meeting will provide a platform to discuss the most pressing challenges must be overcome for these therapeutics to achieve their full clinical potential.
With 20+ hours of content, interactive workshops and 5 hours+ of networking with your fellow drug developers, this is the only European conference solely focused on the application of cannabinoids for pharmaceutical use in a range of disease indications.
Join us as we unite experts from across large pharma, innovative biotechs, academia and solution providers to overcome all the end to end challenges which are holding back therapeutic and commercial success in cannabinoid-based drug development.
“The inspiration in this meeting is the merging of minds in the field to better understand hurdles that become business opportunities”
Eyal Ballan, Co-founder and CTO, Cannabics Pharmaceuticals
“Cannabinoid medicine has incredible potential that has only recently become the object of rigorous scientific investigation. It is important for those working in the field to share knowledge and ideas to expedite the understanding and development of these new therapies”
Andrea Leone-Bay, CSO and Founder, Receptor Life Sciences
“The present summit is a unique opportunity to exchange ideas and share achievements in our multifaceted area of development new therapeutics based on and derived from phyto-cannabinoids”
Shimon Lecht, Chief R&D Officer, CannRx